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Major obstetric haemorrhage remains a signiﬁcant cause of maternal morbidity and mortality. Previous case reports suggest the
potential beneﬁt of recombinant activated factor VII (rFVIIa: NovoSeven
R) as a haemostatic agent. We performed a retrospective
review of the use of rVIIa in major obstetric haemorrhage in the Northern Region between July 2004 and February 2007. Fifteen
women received rFVIIa. The median patient age was 34 years. Major haemorrhage occurred antepartum (5 patients), intrapartum
(1),andpostpartum(9).Allwomenreceivedaninitialdoseof90mcg/kgrFVIIaandonereceived2furtherdoses.Bleedingstopped
or decreased in 12 patients (80%). Additional measures included antiﬁbrinolytic and uterotonic agents, Rusch balloon insertion,
uterine curettage/packing, and vessel embolisation. Eight patients required hysterectomy. All women survived to discharge from
hospital. No adverse events, including thrombosis, were recorded. This study provides further support for the safety and eﬃcacy
of rFVIIa as adjunct therapy in major obstetric haemorrhage.
Copyright © 2009 Charlotte Bomken et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Obstetric haemorrhage remains a signiﬁcant cause of mater-
nal morbidity and mortality. Worldwide, life-threatening
haemorrhage occurs in 10% of all live births [1]. In the UK,
obstetric haemorrhage has a mortality rate of 8.5 per million
maternities; the most recent triennial report of the Conﬁ-
dentialEnquiryintoMaternalandChildHealth(2000–2002)
identiﬁed 17 maternal deaths due to obstetric haemorrhage.
Care was described as potentially substandard in 71% of
these cases. This mostly referred to organisational problems,
in particular deﬁciencies in interprofessional communica-
tion [1]. The management of major obstetric haemorrhage
remains challenging, requiring both surgical and medical
interventions, sometimes resulting in hysterectomy. A mul-
tidisciplinary team approach involving clear communication
between pathology laboratory staﬀ, obstetricians, midwives,
haematologists, and radiologists is therefore essential, and
clear written guidelines for intervention can be helpful.
In recent years, the oﬀ-licence use of rFVIIa as a
haemostatic agent in the management of life-threatening
haemorrhage in a variety of clinical settings has become well
recognised [2–8]. There are several published case reports
and small case series documenting the eﬀective use of rFVIIa
in the management of major obstetric haemorrhage [9–15].
However, large case series and randomised controlled trials
have not been conducted. We present our experience of the
administration of rFVIIa in a consecutive cohort of women
with major obstetric haemorrhage in the Northern region of
England and propose a guideline for appropriate use in this
setting.
2. Methods
2.1.ProtocolfortheAdministrationofrFVIIa. Administration
of rFVIIa for major obstetric haemorrhage was according
to a regional consensus protocol. RFVIIa was indicated2 Obstetrics and Gynecology International
if signiﬁcant bleeding (at an estimated rate of greater
than 200mL/hr) continued despite optimal medical/surgical
measures and blood component replacement therapy, to
achieve a platelet count greater than 50 × 109/L, a ﬁbrinogen
>1.0g/L, and a prothrombin time and activated partial
thromboplastin time <1.5 times greater than the upper limit
of normal. Authorisation by a Consultant Haematologist
was required prior to use of rFVIIa. A dose of 90mcg/kg
was recommended, with a second dose 3 hours later if
an initial response was not obtained. We proposed that a
maximum of two doses should be given, with further doses
being given only in exceptional circumstances, for exam-
ple, where the obstetrician, haematologist, and anaesthetist
agreed that further doses might be useful, particularly if
exsanguination seemed likely. Platelet count, prothrombin
time (PT), activated partial thromboplastin time (APTT),
and Clauss ﬁbrinogen were measured immediately before,
and 15 minutes after, administration of the ﬁrst dose.
Bilateral lower limb Doppler ultrasound was performed after
3–5 days to assess the presence of deep venous thrombosis
(DVT).
2.2. Data Collection. Data were obtained by retrospective
review of patients’ case notes and laboratory records.
Details of patient age, gestation, circumstances leading
to the haemorrhagic event, dose of rFVIIa and number
of doses administered, and additional measures taken to
achieve haemostasis were recorded. Clinical response (bleed-
ing unchanged, bleeding decreased, or bleeding stopped)
was assessed subjectively by the attending obstetrician or
anaesthetist 1 hour after the ﬁrst dose of rFVIIa. Laboratory
results (platelet count, PT, APTT, and Clauss ﬁbrinogen),
and details of blood components transfused during the
24 hours before and after rFVIIa administration were
noted. Case notes were examined for any reported throm-
botic events occurring within 7 days of administration of
rFVIIa.
3.StatisticalAnalysis
Coagulation parameters and blood component use pre and
post rFVIIa administration were analysed using Wilcoxon
signed rank test for paired nonparametric data. A P value of
<.05 was considered to be signiﬁcant.
4. Results
4.1. Patient Demographics. Fifteen women received rFVIIa
for major obstetric haemorrhage over a 31-month period
between July 2004 and February 2007 (Table 1). Median
age was 34 years (range: 20–46 years). Fourteen women
had singleton pregnancies, one had a twin pregnancy. One
patient (Patient 9) was a Jehovah’s Witness who did not
consent to the administration of blood products.
4.2. Indication for rFVIIa. Indications for the use of
rFVIIa were as follows: antepartum haemorrhage, 5 patients;
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Figure 1: Red cell transfusion requirements within 24 hours
before and after the administration of rVIIa for major obstetric
haemorrhage.
intrapartum haemorrhage, 1 patient; and postpartum haem-
orrhage, 9 patients. Cause of bleeding was identiﬁed as
follows: uterine atony, 6 patients; complications following
Caesarean section, 2 patients; placenta praevia, 3 patients;
uterine perforation, 1 patient; abruption, 2 patients; and
uterine eversion, 1 patient.
4.3. Dosing and Timing of Administration of rFVIIa. All
patients received the recommended dose of rFVIIa of
90mcg/kg. The median time from start of bleeding to
administration of the ﬁrst dose of rFVIIa was 4 hours and
5m i n u t e s( r a n g e1h o u r – 2 0h o u r s3 3m i n u t e s ) .1 4p a t i e n t s
received 1 dose of rFVIIa and 1 patient (patient 7) received 3
doses.
4.4. Response to rFVIIa: Clinical Response, Coagulation Pa-
rameters, and Blood Transfusion Requirements. A clinical
response to rFVIIa (deﬁned as bleeding decreased or stopped
at 1 hour post administration) was seen in 12/15 (80%)
patients. The median number of units of blood components
transfused following rFVIIa was observed to be lower than
beforerFVIIa (Table 2).However, asigniﬁcantdiﬀerence was
only demonstrated for transfusion of red cells (P = .034)
(Figure 1). The relatively low number of nonresponding
patients did not allow for subgroup analysis of responders
versus nonresponders.
Coagulation data were collected for all patients. Median
pre and posttreatment PTs were 15 seconds (range: 13–29)
and 10 seconds (range: 6.8–28); P = .007. Median pre-
and posttreatment APTTs were 50 seconds (range: 21–160)
and 33 seconds (range: 26.5–150); P = .025. No signiﬁcant
change was seen in platelet count (P = .188) or Clauss
ﬁbrinogen (P = .073) (Table 3).Obstetrics and Gynecology International 3
Table 1: Clinical indication and response to rFVIIa following major obstetric haemorrhage. rFVIIa—recombinant activated factor VII,
TAH—total abdominal hysterectomy.
Pt no. Maternal age
(years) Cause of bleeding
Time from start
of bleeding to
rFVIIa
administration
(hours:minutes)
No. of rFVIIa
doses
administered
Measures taken to
secure
haemostasis
before rFVIIa
Measures taken
to secure
haemostasis
after rFVIIa
Blood loss
following rFVIIa
1 33 Uterine atony 12:35 1
Uterotonics,
curettage, uterine
packing
Nil Stopped
23 4 Post emergency
Caesarean section 20:33 1
Aprotinin,
ligation of broad
ligament bleed
point
Bilateral iliac
artery ligation,
splenectomy
Stopped
33 0
Retained
placenta, uterine
perforation
2:00 1
TAH (rFVIIa
given
intraoperatively)
Nil Stopped
43 0 Placental
abruption 9:15 1 Uterotonics Nil Stopped
53 8
Uterine atony
following exit
procedure
1:59 1 Uterotonics Nil Decreased
62 0
Uterine atony,
vaginal
lacerations
2:57 1 Uterotonics,
Rusch balloon Nil Decreased
73 4
Intrapartum
bleeding with
uterine atony
following
emergency
Caesarean section
5:10 3
Uterotonics,
Rusch balloon,
TAH (1st dose
rFVIIa given
intraoperatively)
2nd rVIIa
followed by 4
vessel
embolisation,
3rd rFVIIA
followed by
repair bladder
tear and further
embolisation
Decreased
84 6
Placenta accreta
and placenta
praevia,
4:35 1 TAH
Laparotomy but
no bleeding
point found.
Decreased
93 2
Placenta praevia
(Jehovah’s
Witness)
8:00 1
Uterotonics,
antiﬁbrinolytics,
B-Lynch suture
TAH Decreased
10 36
Placental
abruption during
road traﬃc
accident
5:00 1
Uterotonics,
laparotomy and
intra-abdominal
packing
Nil Decreased
11 38 Placenta praevia 3:05 1
Balloon
tamponade,
vaginal packing
Nil Decreased4 Obstetrics and Gynecology International
Table 1: Continued.
Pt no. Maternal age
(years) Cause of bleeding
Time from start
of bleeding to
rFVIIa
administration
(hours:minutes)
No. of rFVIIa
doses
administered
Measures taken to
secure
haemostasis
before rFVIIa
Measures taken
to secure
haemostasis
after rFVIIa
Blood loss
following rFVIIa
12 36 Uterine eversion 1:00 1
Uterotonics,
uterine packing,
vessel
embolisation,
TAH (rFVIIa
given
intraoperatively)
Repeat
laparotomy and
abdominal
packing
Decreased
13 21 Placenta praevia 3:30 1 Uterotonics,
antiﬁbrinolytics TAH Unchanged
14 43
Post elective
Caesarean
section, broad
ligament tear
4:05 1 Laparotomy and
repair of tear
Subtotal
hysterectomy Unchanged
15 20 Uterine atony 3:00 1
Uterotonics,
uterine packing,
B-Lynch suture,
iliac artery
ligation,
TAH Unchanged
4.5. Additional Measures Taken to Achieve Haemostasis. Prior
to rFVIIa administration, additional measures to control
blood loss included blood product support, uterotonic
agents, antiﬁbrinolytic agents, uterine packing, insertion
of Rusch balloon, B-lynch suture, and vessel embolisa-
tion/ligation. A hysterectomy was performed in 4 patients
prior to (1 patient) or concurrent with (3 patients) the
administration of rFVIIa. Following the administration
of rFVIIa, additional measures were required to achieve
haemostasis in 7 patients. In 4 of these patients, these
measures included a total (3 patients) or subtotal (1 patient)
hysterectomy.
5. Outcome
No clinical evidence of venous or arterial thrombosis was
identiﬁed in any of the ﬁfteen women who received rFVIIa.
Of the nine women with a documented lower limb Doppler
ultrasound result, no radiological evidence of deep vein
thrombosis was recorded. All patients survived to discharge
from hospital.
6. Discussion
Although the death rate due to obstetric haemorrhage has
fallen over the last 40 years, the most recent triennial
report for the United Kingdom has seen an increase in
maternal mortality due to haemorrhage from 3.3 to 8.5 per
million maternities [1]. Obstetric haemorrhage can progress
rapidly and is strongly associated with the development of
disseminated intravascular coagulation (DIC) [16]. Delayed
correction of DIC is associated with a signiﬁcant increase in
morbidity and mortality. Rapid correction of coagulopathy
with ongoing regular monitoring of coagulation status is
often diﬃcult to coordinate in the setting of acute life-
threatening obstetric haemorrhage. However, this is vital to
the successful management of such cases. It has therefore
been proposed that the management of major obstetric
haemorrhage should take place in conjunction with a
haematologist to ensure the early identiﬁcation and rapid
correction of DIC, with the subsequent administration of
rFVIIa where appropriate, and the frequent monitoring
required in bleeding patients [16].
rFVIIa works locally by directly forming a complex with
exposed tissue factor on subendothelial cells. This complex
activates factors IX and X leading to the generation of
small amounts of thrombin. This in turn activates factors
V and VIII and platelets perpetuating thrombin generation
and resulting in a “thrombin burst.” The action of rFVIIa
is limited to the site of tissue injury and tissue factor
exposure. This is particularly useful in the obstetric setting
where there is often bleeding from a large raw area of
exposed tissue. Action of rFVIIa is dependant on the
presence of adequate numbers of circulating platelets and
adequate ﬁbrinogen concentration. Previous reports have
shown that the improvements in laboratory markers of
DIC, by the administration of blood components prior to
the administration of rFVIIa, are associated with a better
response to rFVIIa treatment [4]. It is also recognised thatObstetrics and Gynecology International 5
Table 2: Blood product requirements before and after the administration of rFVIIa for major obstetric haemorrhage.
Pt no.
FFP transfused Cryoprecipitate Platelets transfused Red cells transfused
(units) transfused (units) (pools) (units)
Pre Post Pre Post Pre Post Pre Post
1 2 0 1 0 0018 4
2 12 0 10 0 2 0 21 3
3 4 09020 1 2 0
4 4 055209 2
5 4 40 1 0 03 1 1 11
6 401 00 0 21 4 12
7 7 3 184 211 2 2 1 52
8 1 0 63022 2 0 10
9 0 000000 0
1 0 1 2 02 0 1 02 01 8 0
1 1 4 00000 1 1 3
1 2 61 51 01 0 2 5 2 2 20
1 3 87 01 02 21 5 14
14 10 0 10 0 1 0 20 10
1 5 4 5 3 0 0106 6
M e d i a n 4 09010 1 4 6
P-value
∗ 0.127 0.413 0.700 0.034
∗Wilcoxon signed-rank test is shown.
Table 3: Coagulation parameters before and after the administration of rFVIIa for major obstetric haemorrhage. Normal ranges:
Prothrombin time 10–13 seconds; Activated partial thromboplastin time 25–37 seconds; Fibrinogen 2.1–4.8 seconds.
Pt no.
Prothrombin time Activated partial Platelet count Fibrinogen
(seconds) thromboplastin time (seconds) (×109/L) (g/L)
Pre Post Pre Post Pre Post Pre Post
1 1 4 9 3 03 09 39 61 . 7 1.5
2 21 13 49 33 106 85 1.4 2.6
3 16 10 52 29 129 103 0.9 2.4
4 1 51 03 42 58 99 30 . 9 1.9
5 16 11 64 57 160 125 1.3 1.7
6 1 81 16 03 16 84 80 . 4 1.4
7 29 12 160 93 6 22 0.6 0.9
8 1 51 03 43 74 84 51 . 5 2.1
9 1 5 9 3 93 08 9 1 1 922.1
1 0 1 5 9 6 03 06 46 90 . 9 3.6
1 1 1 5 9 5 03 77 66 20 . 9 0.8
12 13 10 50 35 35 57 2.1 2.3
13 14 28 31 150 308 28 4.1 1.3
14 9.2 6.8 101 41 51 34 1.9 3.36
15 16.4 10.6 21 26.5 327 88 2.6 2
M e d i a n 1 51 05 03 38 96 91 . 4 2 . 0
P-values∗ 0.007 0.025 0.188 0.073
∗Wilcoxon signed-rank test is shown.6 Obstetrics and Gynecology International
Table 4
Guidance fortheuse of rFVIIa in majorobstetrichaemorrhage
(i) Use of rFVIIa should be considered in major obstetric haemorrhage:
-which continues despite optimal blood product replacement and obstetric measures.
-where uterine artery ligation/embolisation or hysterectomy are under consideration.
-with clinical haemostatic failure (i.e., oozing from multiple sites), where there is unavoidable delay in the provision of
blood products.
-in women who refuse blood or blood components, for example, Jehovah’s Witness
(ii) A dose of 90µg/kg is recommended
(iii) Use of rFVIIa should be authorised by a Consultant Haematologist or Consultant Obstetric Anaesthetist prior to administration.
(iv) A single standard dose should be kept in delivery suite to facilitate rapid administration in appropriate circumstances.
(v) Use of rFVIIa should not be seen as an alternative to surgical haemostasis or correction of coagulopathy with blood products. Before
administration of rFVIIa, the following laboratory indices are desirable;
–Prothrombin time < 1.5 × upper limit of normal
–Clauss ﬁbrinogen > 1.0g/L
–Platelet count > 50 × 109/L
(vi) Along with the above laboratory indices a pH > 7.1 is also desirable for optimal eﬀect.
(vii) Further doses should only be given in exceptional circumstances where agreed by the multidisciplinary team, for example, where
exsanguination seems likely.
correction of acidosis is an important aspect in the success
of rFVIIa. Measurement of pH is not a routine investigation
in the management of obstetric haemorrhage within our
region. We have therefore not included pH data in this study.
This case series documents a clinical response (bleeding
stopped or decreased) to rFVIIa in 80% of patients, which
is comparable to previous documented clinical response
rates described in case reports and small series in obstetric
haemorrhage [9–15]. It is also comparable to the response
to rFVIIa reported in life-threatening haemorrhage from
all causes, where the median response rate is reported
as 74% [2–8] .T h e r eh a v eb e e nn ol a r g ec a s es e r i e so r
randomised controlled trials on the use of rFVIIa in obstetric
haemorrhage. However, a recently published case series of 26
patients reviewing the use of rFVIIa in post-partum haem-
orrhage, documented a good response (bleeding <1000mL
post administration) or moderate response (ongoing blood
loss >1000mL without the need for additional surgical or
radiological intervention) to rFVIIa treatment in 61% of
patients [9]. We believe that even a reduction in blood loss
that is suﬃcient to allow additional procedures to achieve
complete haemostasis is clinically signiﬁcant.
The use of blood, FFP, platelets, and cryoprecipitate was
reducedinthisseriesinthemajorityofpatientsfollowingthe
administration of rFVIIa, but not in all patients. Where large
volume blood loss occurred, adequate red cell replacement
may take time to achieve, with patients requiring ongoing
transfusion despite an observed decrease in bleeding. The
number of red cell units required may therefore be a poor
indicator of response to rFVIIa. The relatively small number
of patients makes this series vulnerable to the eﬀects of single
patients. 1 patient in our series (patient 7) received rFVIIa
formassiveintrapartumhaemorrhagefollowingintrauterine
foetal death at 30 weeks gestation with the development
of subsequent DIC, requiring emergency caesarean section.
Despite blood product support, uterotonic agents and
antiﬁbrinolytic agents, the coagulopathy worsened and she
developedincreasingbloodproductrequirements.Therewas
a documented reduction in blood loss initially following
administration of rFVIIa. However, bleeding subsequently
worsened and the patient required a hysterectomy. The
patient received in addition a further 2 doses of rFVIIa,
with an observed decrease in bleeding after each dose, and
required arterial embolisation of 4 vessels with subsequent
haemostasis 12 hours after her original presentation. Despite
the eﬀects of this important case, our data suggest an
overall decrease in blood component use following the
administration of rFVIIa. To those patients who responded
well to rFVIIa, this is clinically very important. It reduces
theirexposuretobloodproductsandtherebyreducestherisk
of transfusion reaction, transfusion transmitted infection,
and alloantibody formation, and prevents worsening of
coagulopathy by the eﬀects of dilution, hypothermia, and
acidosis.
In addition to blood component support, all patients in
this series required further obstetric or surgical measures to
control bleeding. In 8 patients, vessel ligation, embolisation,
or hysterectomy was performed prior to the administration
of rFVIIa. Bleeding rate was unchanged in 2 of these patients
following rFVIIa administration and both patients required
a hysterectomy. However, these 2 patients had additional risk
factors (coagulopathy, administration of >10 units of blood,
acidosis and hypothermia) prior to rFVIIa administration.
All of these risk factors have been shown to be associated
withaworseoutcomefollowingtheadministrationofrFVIIa
[2–8]. A further 2 patients required vessel embolisation
following rFVIIa administration. Both patients suﬀered
uterine atony (1 following uterine eversion) which failed toObstetrics and Gynecology International 7
settle with uterotonic agents. In both patients, hysterectomy
was performed prior to the administration of rFVIIa but
bleedingcontinued.InbothpatientsaresponsetorFVIIawas
documented initially but bleeding subsequently worsened.
Both patients were found to have bleeding from major blood
vessels. One patient required radiological embolisation to a
bleeding pelvic artery and subsequent re-laparotomy before
bleeding was controlled. The second patient received 3 doses
of rFVIIa prior to embolisation of both iliac arteries, right
circumﬂex artery and right internal pudendal artery.
Emergency hysterectomy is a procedure associated with
a risk of signiﬁcant long-term maternal morbidity [17, 18].
Avoidance, where possible, signiﬁcantly reduces morbidity
and preserves future fertility. As an adjunct to obstetric and
surgicalmeasures,webelievethatconsiderationofrFVIIause
shouldbegivenearly,priortohysterectomyorvesselligation.
Proposed guidance for the use of rFVIIa in major obstetric
haemorrhage is detailed in Table 4. It is clear that rFVIIa
is unlikely to be eﬀective as a sole measure in the presence
of bleeding from large vessels. It may however slow the
rate bleeding and prevent further deterioration by delaying
the onset of DIC and by reducing the number of units of
blood transfused, thus reducing hypothermia, acidosis, and
dilutional coagulopathy.
No thrombotic events were documented in our series
despite the relative prothrombotic state of pregnancy. Many
of the thrombotic events seen in association with rFVIIa
are arterial and occur in patients with preexisting vascular
risk factors [19], and reports have documented a low
thromboembolic risk in previously healthy patients with
major haemorrhage even in the presence of DIC [8, 20].
Nevertheless, it was very reassuring that this potentially
signiﬁcant event was not observed in our series, providing
further evidence for the safety of rFVIIa in major obstetric
haemorrhage.
7. Conclusions
This report provides evidence to support the ongoing use
of rFVIIa in the management of life-threatening obstetric
haemorrhage as a successful adjunct to optimal medical and
obstetric intervention. It is unlikely that we will see ran-
domised control trial data comparing the use of rFVIIa with
placebo given the practical diﬃculties of formally consenting
and then randomising patients who are experiencing life-
threatening obstetric haemorrhage. It would be diﬃcult to
justify withholding a treatment that can be eﬃcacious in
obstetric haemorrhage in favour of placebo agents in this
setting. We therefore rely on data collected from case series.
Larger series are required in order to clarify the beneﬁt of
rFVIIa use and to allow the creation of clear guidelines for
theestablishedbutoﬀ-licenceuseofthisagent.Tocollateand
analyse data on the use of rVIIa in obstetric haemorrhage,
the Northern Europe Factor VIIa in Obstetric Haemorrhage
(NEFOH) Registry has been formed. This allow for the
collection of information on a larger number of cases with
the intention of providing further guidance on the future use
of rVIIa in the management of obstetric haemorrhage.
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